194 related articles for article (PubMed ID: 24211136)
1. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
Winkler DG; Faia KL; DiNitto JP; Ali JA; White KF; Brophy EE; Pink MM; Proctor JL; Lussier J; Martin CM; Hoyt JG; Tillotson B; Murphy EL; Lim AR; Thomas BD; Macdougall JR; Ren P; Liu Y; Li LS; Jessen KA; Fritz CC; Dunbar JL; Porter JR; Rommel C; Palombella VJ; Changelian PS; Kutok JL
Chem Biol; 2013 Nov; 20(11):1364-74. PubMed ID: 24211136
[TBL] [Abstract][Full Text] [Related]
2. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
Boyle DL; Kim HR; Topolewski K; Bartok B; Firestein GS
J Pharmacol Exp Ther; 2014 Feb; 348(2):271-80. PubMed ID: 24244039
[TBL] [Abstract][Full Text] [Related]
3. Two birds with one stone: dual p110δ and p110γ inhibition.
Okkenhaug K
Chem Biol; 2013 Nov; 20(11):1309-10. PubMed ID: 24267274
[TBL] [Abstract][Full Text] [Related]
4. The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation.
Takeda M; Ito W; Tanabe M; Ueki S; Kihara J; Kato H; Tanigai T; Kayaba H; Sasaki T; Chihara J
Int Arch Allergy Immunol; 2010; 152 Suppl 1():90-5. PubMed ID: 20523070
[TBL] [Abstract][Full Text] [Related]
5. Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death.
Suárez-Fueyo A; Barber DF; Martínez-Ara J; Zea-Mendoza AC; Carrera AC
J Immunol; 2011 Sep; 187(5):2376-85. PubMed ID: 21810603
[TBL] [Abstract][Full Text] [Related]
6. Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity.
Safina BS; Sweeney ZK; Li J; Chan BK; Bisconte A; Carrera D; Castanedo G; Flagella M; Heald R; Lewis C; Murray JM; Nonomiya J; Pang J; Price S; Reif K; Salphati L; Seward EM; Wei B; Sutherlin DP
Bioorg Med Chem Lett; 2013 Sep; 23(17):4953-9. PubMed ID: 23867164
[TBL] [Abstract][Full Text] [Related]
7. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
[TBL] [Abstract][Full Text] [Related]
8. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K
Allen RA; Brookings DC; Powell MJ; Delgado J; Shuttleworth LK; Merriman M; Fahy IJ; Tewari R; Silva JP; Healy LJ; Davies GCG; Twomey B; Cutler RM; Kotian A; Crosby A; McCluskey G; Watt GF; Payne A
J Pharmacol Exp Ther; 2017 Jun; 361(3):429-440. PubMed ID: 28442583
[TBL] [Abstract][Full Text] [Related]
9. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
Rommel C; Camps M; Ji H
Nat Rev Immunol; 2007 Mar; 7(3):191-201. PubMed ID: 17290298
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide 3-kinase-delta inhibitor reduces vascular permeability in a murine model of asthma.
Lee KS; Park SJ; Kim SR; Min KH; Jin SM; Puri KD; Lee YC
J Allergy Clin Immunol; 2006 Aug; 118(2):403-9. PubMed ID: 16890765
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
12. Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.
Gonzalez-Lopez de Turiso F; Shin Y; Brown M; Cardozo M; Chen Y; Fong D; Hao X; He X; Henne K; Hu YL; Johnson MG; Kohn T; Lohman J; McBride HJ; McGee LR; Medina JC; Metz D; Miner K; Mohn D; Pattaropong V; Seganish J; Simard JL; Wannberg S; Whittington DA; Yu G; Cushing TD
J Med Chem; 2012 Sep; 55(17):7667-85. PubMed ID: 22876881
[TBL] [Abstract][Full Text] [Related]
13. PI3Kγδ inhibition suppresses key disease features in a rat model of asthma.
Pinkerton JW; Preite S; Piras A; Zervas D; Markou T; Freeman MS; Hofving T; Ivarsson E; Bonvini SJ; Brailsford W; Yrlid L; Belvisi MG; Birrell MA
Respir Res; 2024 Apr; 25(1):175. PubMed ID: 38654248
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse.
Suárez-Fueyo A; Rojas JM; Cariaga AE; García E; Steiner BH; Barber DF; Puri KD; Carrera AC
J Immunol; 2014 Jul; 193(2):544-54. PubMed ID: 24935930
[TBL] [Abstract][Full Text] [Related]
15. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
Doukas J; Eide L; Stebbins K; Racanelli-Layton A; Dellamary L; Martin M; Dneprovskaia E; Noronha G; Soll R; Wrasidlo W; Acevedo LM; Cheresh DA
J Pharmacol Exp Ther; 2009 Mar; 328(3):758-65. PubMed ID: 19056934
[TBL] [Abstract][Full Text] [Related]
16. The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.
Chiu H; Mallya S; Nguyen P; Mai A; Jackson LV; Winkler DG; DiNitto JP; Brophy EE; McGovern K; Kutok JL; Fruman DA
Front Immunol; 2017; 8():747. PubMed ID: 28713374
[TBL] [Abstract][Full Text] [Related]
17. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice.
Durand CA; Richer MJ; Brenker K; Graves M; Shanina I; Choi K; Horwitz MS; Puri KD; Gold MR
Autoimmunity; 2013 Feb; 46(1):62-73. PubMed ID: 23039284
[TBL] [Abstract][Full Text] [Related]
18. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
19. Effects of various anti-inflammatory drugs on type II collagen-induced arthritis in rats.
Phadke K; Carroll J; Nanda S
Clin Exp Immunol; 1982 Mar; 47(3):579-86. PubMed ID: 6979443
[TBL] [Abstract][Full Text] [Related]
20. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
